- Phosphatidylinositol 3-kinase (PI3K) inhibitors are effective treatments for B-cell malignancies, but many have unique toxicities based on the differential expression of the four different PI3K isoforms (Î±, Î², Î´, Î³) in different body tissues and organs.
- Unique toxicities include autoimmune effects (colitis, hepatitis, pneumonitis, rash), opportunistic infections (cytomegalovirus, Pneumocystis jirovecii pneumonia), hypertension, hyperglycemia, and neuropsychiatric changes. Inhibition of different PI3K isoforms is associated with different toxicities.
- Many toxicities associated with PI3K inhibitors can be effectively managed while continuing treatment, while others require discontinuation of the causative agent. Prompt attention to reported toxicities and adherence to prescribing information and expert guidelines are essential for patients using these therapies.